Eads & Heald Wealth Management Sells 236 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eads & Heald Wealth Management cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,383 shares of the company’s stock after selling 236 shares during the period. Eads & Heald Wealth Management’s holdings in IDEXX Laboratories were worth $985,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. International Assets Investment Management LLC increased its holdings in IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after buying an additional 316,048 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of IDEXX Laboratories by 696.0% during the 2nd quarter. Clearbridge Investments LLC now owns 352,814 shares of the company’s stock valued at $171,891,000 after acquiring an additional 308,493 shares during the period. Seilern Investment Management Ltd purchased a new stake in IDEXX Laboratories in the fourth quarter worth $113,104,000. Finally, Vontobel Holding Ltd. increased its holdings in IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after acquiring an additional 213,731 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IDXX. JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Barclays cut their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Stock Up 1.9 %

NASDAQ IDXX opened at $427.33 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The stock has a market capitalization of $34.99 billion, a PE ratio of 41.21, a PEG ratio of 3.53 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The business’s 50-day moving average is $423.24 and its 200 day moving average is $457.45.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the firm earned $2.53 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.